Literature DB >> 19143012

Light therapy and supplementary Riboflavin in the SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis (FALS).

Helina Moges1, Olavo M Vasconcelos, William W Campbell, Rosemary C Borke, Jennifer Anne McCoy, Lauren Kaczmarczyk, Ji Feng, Juanita J Anders.   

Abstract

BACKGROUND AND
OBJECTIVE: Familial amyotrophic lateral sclerosis (FALS) is a neurodegenerative disease characterized by progressive loss of motor neurons and death. Mitochondrial dysfunction and oxidative stress play an important role in motor neuron loss in ALS. Light therapy (LT) has biomodulatory effects on mitochondria. Riboflavin improves energy efficiency in mitochondria and reduces oxidative injury. The purpose of this study was to examine the synergistic effect of LT and riboflavin on the survival of motor neurons in a mouse model of FALS. STUDY DESIGN/
MATERIALS AND METHODS: G93A SOD1 transgenic mice were divided into four groups: Control, Riboflavin, Light, and Riboflavin+Light (combination). Mice were treated from 51 days of age until death. A single set of LT parameters was used: 810 nm diode laser, 140-mW output power, 1.4 cm(2) spot area, 120 seconds treatment duration, and 12 J/cm(2) energy density. Behavioral tests and weight monitoring were done weekly. At end stage of the disease, mice were euthanized, survival data was collected and immunohistochemistry and motor neuron counts were performed.
RESULTS: There was no difference in survival between groups. Motor function was not significantly improved with the exception of the rotarod test which showed significant improvement in the Light group in the early stage of the disease. Immunohistochemical expression of the astrocyte marker, glial fibrilary acidic protein, was significantly reduced in the cervical and lumbar enlargements of the spinal cord as a result of LT. There was no difference in the number of motor neurons in the anterior horn of the lumbar enlargement between groups.
CONCLUSIONS: The lack of significant improvement in survival and motor performance indicates study interventions were ineffective in altering disease progression in the G93A SOD1 mice. Our findings have potential implications for the conceptual use of light to treat other neurodegenerative diseases that have been linked to mitochondrial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19143012     DOI: 10.1002/lsm.20732

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  18 in total

Review 1.  The nuts and bolts of low-level laser (light) therapy.

Authors:  Hoon Chung; Tianhong Dai; Sulbha K Sharma; Ying-Ying Huang; James D Carroll; Michael R Hamblin
Journal:  Ann Biomed Eng       Date:  2011-11-02       Impact factor: 3.934

Review 2.  Role of low-level laser therapy in neurorehabilitation.

Authors:  Javad T Hashmi; Ying-Ying Huang; Bushra Z Osmani; Sulbha K Sharma; Margaret A Naeser; Michael R Hamblin
Journal:  PM R       Date:  2010-12       Impact factor: 2.298

Review 3.  Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis.

Authors:  Richard S Bedlack; Nanette Joyce; Gregory T Carter; Sabrina Paganoni; Chafic Karam
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 4.  Potential for transcranial laser or LED therapy to treat stroke, traumatic brain injury, and neurodegenerative disease.

Authors:  Margaret A Naeser; Michael R Hamblin
Journal:  Photomed Laser Surg       Date:  2011-07       Impact factor: 2.796

5.  Comparison of the effects of pulsed and continuous wave light on axonal regeneration in a rat model of spinal cord injury.

Authors:  Xingjia Wu; Helina Moges; Luis DeTaboada; Juanita Anders
Journal:  Lasers Med Sci       Date:  2011-09-10       Impact factor: 3.161

6.  Monitoring systemic oxidative stress in an animal model of amyotrophic lateral sclerosis.

Authors:  Francisco Javier Miana-Mena; Cristina González-Mingot; Pilar Larrodé; María Jesús Muñoz; Sara Oliván; Lorena Fuentes-Broto; Enrique Martínez-Ballarín; Russel J Reiter; Rosario Osta; Joaquín José García
Journal:  J Neurol       Date:  2010-11-25       Impact factor: 4.849

7.  Focused cerebellar laser light induced hyperthermia improves symptoms and pathology of polyglutamine disease SCA1 in a mouse model.

Authors:  Scoty M Hearst; Qingmei Shao; Mariper Lopez; Drazen Raucher; Parminder J S Vig
Journal:  Cerebellum       Date:  2014-10       Impact factor: 3.847

8.  Low-level laser therapy (LLLT) reduces oxidative stress in primary cortical neurons in vitro.

Authors:  Ying-Ying Huang; Kazuya Nagata; Clark E Tedford; Thomas McCarthy; Michael R Hamblin
Journal:  J Biophotonics       Date:  2012-12-27       Impact factor: 3.207

Review 9.  Palliative Care Issues in Amyotrophic Lateral Sclerosis: An Evidenced-Based Review.

Authors:  Chafic Y Karam; Sabrina Paganoni; Nanette Joyce; Gregory T Carter; Richard Bedlack
Journal:  Am J Hosp Palliat Care       Date:  2014-09-08       Impact factor: 2.500

10.  Transcranial low-level laser therapy (810 nm) temporarily inhibits peripheral nociception: photoneuromodulation of glutamate receptors, prostatic acid phophatase, and adenosine triphosphate.

Authors:  Marcelo Victor Pires de Sousa; Cleber Ferraresi; Masayoshi Kawakubo; Beatriz Kaippert; Elisabeth Mateus Yoshimura; Michael R Hamblin
Journal:  Neurophotonics       Date:  2016-01-25       Impact factor: 3.593

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.